StonvexLoading…
StonvexStonvexStonvexCore line items from BIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.58B | $2.57B | $2.67B | $2.80B |
Operating Income | $47.20M | $269.00M | $337.80M | $482.60M |
Net Income | $759.90M | $-1.84B | $-637.30M | $-3.63B |
EPS (Diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 |
Total Assets | $10.58B | $9.36B | $12.30B | $13.50B |
Total Liabilities | $3.12B | $2.79B | $3.56B | $3.89B |
Cash & Equivalents | $529.80M | $488.10M | $403.80M | $434.20M |
Free Cash Flow OCF − CapEx | $374.60M | $289.60M | $218.20M | $81.60M |
Shares Outstanding | 27.28M | 28.21M | 29.21M | 29.79M |